Modulation of double-stranded RNA pattern recognition receptor signaling in ovarian cancer cells promotes inflammatory queues
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1437 views | HTML 2001 views | ?
Maria Muccioli1,2, Harika Nandigam1,5, Tiffany Loftus1, Manindra Singh1,2, Amritha Venkatesh1,5, Julia Wright1, Michelle Pate1, Kelly McCall2,3,4,5,6 and Fabian Benencia1,2,4,5,6
1Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, 45701, USA
2Interdisciplinary Graduate Program in Molecular and Cellular Biology, Ohio University, Athens, OH, 45701, USA
3Department of Specialty Medicine, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, 45701, USA
4Diabetes Institute at Ohio University, Ohio University, Athens, OH, 45701, USA
5Biomedical Engineering Program, Russ College of Engineering & Technology, Ohio University, Athens, OH, 45701, USA
6Translational Biomedical Sciences Doctoral Program, Ohio University, Athens, OH, 45701, USA
Fabian Benencia, email: [email protected]
Keywords: ovarian cancer; dendritic cells; dsRNA; PRR; chemokines
Received: June 19, 2018 Accepted: October 24, 2018 Published: November 30, 2018
Inflammation and cancer are inter-related, and both pro- and anti-tumorigenic effects are possible in different contexts, highlighting the importance of characterizing specific inflammatory pathways in distinct tumor types. Malignant cells and non-cancerous cells such as fibroblasts, infiltrating leukocytes (i.e., dendritic cells [DC], macrophages, or lymphocytes) and endothelial cells, in combination with the extracellular matrix, constitute the tumor microenvironment (TME). In the last decades, the role of the TME in cancer progression has gained increased attention and efforts directed at abrogating its deleterious effects on anti-cancer therapies have been ongoing. In this context, we investigated the potential of mouse and human ovarian cancer cells to produce inflammatory factors in response to pathogen recognition receptor (PRR) signaling, which might help to shape the biology of the TME. We determined that mouse ovarian tumors generate chemokines that are able to interact with receptors harbored by tumor-associated DCs. We also found that dsRNA triggers significant pro-inflammatory cytokine up-regulation in both human and mouse ovarian tumor cell lines, and that several PRR can simultaneously contribute to the stimulated inflammatory response displayed by these cells. Thus, dsRNA-activated PRRs may not only constitute potentially relevant drug targets for therapies aiming to prevent inflammation associated with leukocyte recruitment, or as co-adjuvants of therapeutic treatments, but also might have a role in development of nascent tumors, for example via activation of cancer cells by microbial molecules associated to pathogens, or with those appearing in circulation due to dysbiosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.